LIKE MAGIC –
Oct. 18, 2024 – The trial, led by Imperial College London, will focus on whether psilocybin – the active compound in magic mushrooms – combined with psychological support, can help to prevent relapse in people who have been addicted to opioids such as heroin. Combining Imperial’s expertise in psychedelics and opioid addiction, the work will be led by Dr David Erritzoe from the Centre for Psychedelic Research.
The trial will recruit those who have recently undergone detoxification from street opioids such as heroin, or opioid replacements like methadone or buprenorphine. Participants will visit Imperial’s NIHR Clinical Research Facility, which is based at Hammersmith Hospital campus and hosted by Imperial College Healthcare NHS Trust, to receive psilocybin therapy.
